Efficacy evaluation of two commercial modified-live virus vaccines against a novel recombinant type 2 porcine reproductive and respiratory syndrome virus

文献类型： 外文期刊

第一作者： Sun, Ying-Feng

作者： Sun, Ying-Feng;Yu, Hai;Sun, Ying-Feng;Zhou, Lei;Bian, Ting;Yang, Han-Chun;Sun, Ying-Feng;Zhou, Lei;Bian, Ting;Yang, Han-Chun;Tian, Xiang-Xue;Ren, Wei-Ke;Lu, Chao;Zhang, Li;Li, Xiu-Li;Cui, Mao-Sheng;Yu, Hai

作者机构：

关键词： Novel recombinant type 2 PRRSV; Commercial MLV vaccines; Efficacy evaluation

期刊名称：VETERINARY MICROBIOLOGY （ 影响因子：3.293； 五年影响因子：3.599 ）

ISSN： 0378-1135

年卷期： 2018 年 216 卷

页码：

收录情况： SCI

摘要： NADC30-like porcine reproductive and respiratory syndrome virus (PRRSV) causing clinical disease outbreaks has been recently reported in China. The recombination occurring among PRRSV strains could lead to the emergence of novel and more virulent viruses. In our previous study, a novel recombinant type 2 PRRSV (TJnh1501) between NADC30-like and modified-live virus (MLV)-like derived from the Chinese highly patho-genic PRRSV was shown to have higher pathogenicity than NADC30-like PRRSV. It remains unknown whether the emergence of the novel recombinant PRRSV strain can lead to variable protection efficacy of the MLV vaccines. In this paper, two typical commercial MLV vaccines were used to evaluate their efficacy to block TJnh1501 infection and onset of clinical symptoms. Our results showed that both MLV vaccines could shorten the period of fever and reduce viral loads in sera, but were not able to reduce the clinical signs and lung lesions indicating that the two commercial MLV vaccines provide limited cross-protection efficacy against the novel recombinant type 2 PRRSV infection. This study gives valuable suggestions for the use of MLV vaccines to control PRRSV infection in the field.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序